Lepodisiran vs Zerlasiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline
Lepodisiran
Developed by Eli Lilly and partners
NCT05565742 · Phase 2 · completed
The trial randomized 320 participants and used double blinding with a placebo control. Its primary endpoint was a statistically significant reduction in Lp(a) versus placebo for all doses, but Lp(a) is a laboratory biomarker rather than a direct clinical outcome, so the findings provide moderate evidence.
Next expected readout: March 2027 · NCT07914738 (registry estimate)
Reported efficacy
Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) (met)
Result source: NCT05565742
Zerlasiran
Developed by Silence Therapeutics
NCT05537571 · Phase 2 · completed
The trial randomized participants to three zerlasiran regimens or placebo and masked both participants and investigators, with 180 participants enrolled. The primary endpoint was met for all active regimens, with statistically significant reductions in lipoprotein(a) versus pooled placebo; however, because the primary endpoint was a surrogate biomarker rather than a clinical outcome, this evidence is rated moderate.
Reported efficacy
Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 (Week 36): SLN360 300 mg Q16W -80.5% (Standard Error 1.99) | SLN360 300 mg Q24W -79.1% (Standard Error 1.94) | SLN360 450 mg Q24W -83.3% (Standard Error 1.92) vs Pooled Placebo 2.3% (Standard Error 1.88) (met)
Result source: NCT05537571
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lepodisiran | Zerlasiran |
|---|---|---|
| LDL-C, % change | —Trial running · NCT06292013 | -14.7% vs 9.3%−24 vs placeboNCT055375718 other results
|
| Non-HDL-C, % change | —Trial running · NCT06292013 | —Not reported |
| ApoB, % change | -9.1% vs 4.3%−13.4 vs placeboNCT0556574219 other results
| -16.4% vs -3.8%−12.6 vs placeboNCT055375718 other results
|
| Lp(a), % change | -74.4% vs 3.1%−77.5 vs placeboNCT0556574225 other results
| -83.3% vs 2.3%−85.6 vs placeboNCT055375718 other results
|
| 3-point MACE (% with event) | —Trial running · NCT06292013 | —Not reported |
LDL-C, % change
- Lepodisiran
- —Trial running · NCT06292013
- Zerlasiran
- -14.7% vs 9.3%−24 vs placeboNCT05537571
8 other results
- -17% vs 8.9% NCT05537571
- -15.5% vs 9.6% NCT05537571
- -19.3% vs 9.3% NCT05537571
- -16.8% vs 9.3% NCT05537571
- -20.9% vs 8.9% NCT05537571
- -18.5% vs 8.9% NCT05537571
- -22.3% vs 9.6% NCT05537571
- -20.1% vs 9.6% NCT05537571
Non-HDL-C, % change
- Lepodisiran
- —Trial running · NCT06292013
- Zerlasiran
- —Not reported
ApoB, % change
- Lepodisiran
- -9.1% vs 4.3%−13.4 vs placeboNCT05565742
19 other results
- -0.9% vs 4.3% NCT05565742
- -10.4% vs 4.3% NCT05565742
- -4.6% vs 4.3% NCT05565742
- -14% vs 1.8% NCT05565742
- -9% vs 1.8% NCT05565742
- -12.6% vs 1.3% NCT05565742
- -12.6% vs 1.3% NCT05565742
- -13.9% vs 0.2% NCT05565742
- -13.9% vs 0.2% NCT05565742
- -0.6% vs 4.3% NCT05565742
- -8.1% vs 4.3% NCT05565742
- -13.8% vs 1.8% NCT05565742
- -9.6% vs 1.3% NCT05565742
- -11.8% vs 0.2% NCT05565742
- 1.4% vs 4.3% NCT05565742
- -2.9% vs 4.3% NCT05565742
- -7.6% vs 1.8% NCT05565742
- -7% vs 1.3% NCT05565742
- -10.2% vs 0.2% NCT05565742
- Zerlasiran
- -16.4% vs -3.8%−12.6 vs placeboNCT05537571
8 other results
- -18% vs -4% NCT05537571
- -18.6% vs -3.6% NCT05537571
- -15% vs -3.8% NCT05537571
- -10.9% vs -3.8% NCT05537571
- -16.4% vs -4% NCT05537571
- -12.6% vs -4% NCT05537571
- -16.9% vs -3.6% NCT05537571
- -13.5% vs -3.6% NCT05537571
Lp(a), % change
- Lepodisiran
- -74.4% vs 3.1%−77.5 vs placeboNCT05565742
25 other results
- -39% vs 3.1% NCT05565742
- -73.8% vs 1.3% NCT05565742
- -52.8% vs 1.3% NCT05565742
- -91.1% vs -0.9% NCT05565742
- -68.1% vs -0.9% NCT05565742
- -96.8% vs -0.8% NCT05565742
- -84.9% vs -0.8% NCT05565742
- -90.5% vs 2.2% NCT05565742
- -90.5% vs 2.2% NCT05565742
- -95.4% vs 2.2% NCT05565742
- -95.4% vs 2.2% NCT05565742
- -95% vs 0.3% NCT05565742
- -76.7% vs 0.3% NCT05565742
- -45.1% vs 1.3% NCT05565742
- -67.7% vs -0.9% NCT05565742
- -84.8% vs -0.8% NCT05565742
- -65.3% vs 2.2% NCT05565742
- -80.4% vs 2.2% NCT05565742
- -77.4% vs 0.3% NCT05565742
- -18.7% vs 1.3% NCT05565742
- -30.8% vs -0.9% NCT05565742
- -47.7% vs -0.8% NCT05565742
- -30.5% vs 2.2% NCT05565742
- -46.2% vs 2.2% NCT05565742
- -38.7% vs 0.3% NCT05565742
- Zerlasiran
- -83.3% vs 2.3%−85.6 vs placeboNCT05537571
8 other results
- -80.5% vs 2.3% NCT05537571
- -79.1% vs 2.3% NCT05537571
- -76% vs 1.1% NCT05537571
- -81.5% vs 1.5% NCT05537571
- -78% vs 1.1% NCT05537571
- -70.7% vs 1.1% NCT05537571
- -81.6% vs 1.5% NCT05537571
- -77.2% vs 1.5% NCT05537571
3-point MACE (% with event)
- Lepodisiran
- —Trial running · NCT06292013
- Zerlasiran
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lepodisiran: 3 of 4 rows · Zerlasiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lepodisiran | Zerlasiran |
|---|---|---|
| Dropout rate | 2.9%400 mga NCT05565742 · Phase 2 show 3 more results2.8%400 mg NCT05565742 · Phase 2 0%96 mg NCT05565742 · Phase 2 2.8%16 mg NCT05565742 · Phase 2 | 2.2%450 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 show 2 more results11.4%300 mg Q16W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 2.3%300 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 |
| Discontinued due to AEs | —400 mga NCT05565742 · Phase 2 show 3 more results—400 mg NCT05565742 · Phase 2 —96 mg NCT05565742 · Phase 2 —16 mg NCT05565742 · Phase 2 | 0%450 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 show 2 more results4.5%300 mg Q16W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 0%300 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 |
| Serious AEs | 15.9%400 mga NCT05565742 · Phase 2 show 3 more results11.1%400 mg NCT05565742 · Phase 2 12.2%96 mg NCT05565742 · Phase 2 2.8%16 mg NCT05565742 · Phase 2 | 11.1%450 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 show 2 more results14.3%300 mg Q16W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 4.5%300 mg Q24W NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 |
| Most frequent reported AEs | 400 mga injection site reaction 11.6% (placebo 1.4%) covid-19 7.2% (placebo 10.1%) nasopharyngitis 7.2% (placebo 8.7%) NCT05565742 · Phase 2 show 3 more results400 mg nasopharyngitis 13.9% (placebo 8.7%) arthralgia 8.3% (placebo 2.9%) injection site reaction 8.3% (placebo 1.4%) NCT05565742 · Phase 2 96 mg influenza 9.5% (placebo 2.9%) injection site reaction 8.1% (placebo 1.4%) nasopharyngitis 8.1% (placebo 8.7%) NCT05565742 · Phase 2 16 mg influenza 11.1% (placebo 2.9%) ovarian cyst 11.1% (placebo 0%) covid-19 5.6% (placebo 10.1%) NCT05565742 · Phase 2 | 450 mg Q24W injection site reaction 82.2% (placebo 8.7%) influenza-like illness 15.6% (placebo 0%) myalgia 15.6% (placebo 4.3%) NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 show 2 more results300 mg Q16W injection site reaction 83.3% (placebo 8.7%) malaise 14.3% (placebo 0%) upper respiratory tract infection 14.3% (placebo 4.3%) NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 300 mg Q24W injection site reaction 81.8% (placebo 8.7%) upper respiratory tract infection 15.9% (placebo 4.3%) covid-19 13.6% (placebo 13%) NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Zerlasiran
show 8 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lepodisiran's landscape · Zerlasiran's landscape